XOMA Announces May 10 Webcast Discussion of First Quarter 2005 Financial Results
Monday May 2, 7:28 pm ET
BERKELEY, Calif.--(BUSINESS WIRE)--May 2, 2005--XOMA Ltd. (Nasdaq:XOMA - News), will issue a news release announcing its first quarter financial results for the quarter ended March 31, 2005 on Monday, May 9, 2005, after financial markets close. This announcement will be followed by a live webcast on Tuesday, May 10, 2005 at 4:00 p.m. Eastern (1:00 p.m. Pacific) with XOMA management discussing the financials and providing a general business update.
The webcast can be accessed via XOMA's website at xoma.com and will be archived and available for replay until close of business on June 10, 2005. To obtain phone access to the live audiocast, dial 1-877-869-7222 (U.S./Canada) and 1-706-679-5933 (international); Conference ID number 5739895. An audio replay will be available beginning two hours following the conclusion of the webcast through 6:00 p.m. Eastern (3:00 p.m. Pacific) on June 10, 2005. Access numbers for the replay are 1-800-642-1687 (U.S./Canada) or 1-706-645-9291 (international); Conference ID number is 5739895.
About XOMA
XOMA develops for commercialization antibody and other protein-based biopharmaceuticals to treat cancer, immune disorders and infectious diseases. The company pipeline includes proprietary products as well as collaborative product development programs with Chiron Corporation, Millennium Pharmaceuticals, Inc., Aphton Corporation and Alexion Pharmaceuticals, Inc. XOMA also has a royalty interest in RAPTIVA®, a product that came from a collaboration with Genentech, Inc., and is approved in over thirty countries for the treatment of moderate-to-severe plaque psoriasis. For more information about XOMA's product pipeline and antibody product development capabilities and technologies, please visit XOMA's website at xoma.com. |
